Medifast (NYSE:MED – Get Free Report) issued its quarterly earnings data on Tuesday. The specialty retailer reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.26, Zacks reports. Medifast had a return on equity of 15.98% and a net margin of 1.09%. Medifast updated its Q1 2025 guidance to -0.500-0.000 EPS.
Medifast Trading Down 1.0 %
Shares of MED traded down $0.16 during mid-day trading on Tuesday, reaching $16.05. The company had a trading volume of 280,528 shares, compared to its average volume of 212,304. Medifast has a fifty-two week low of $14.76 and a fifty-two week high of $49.90. The stock has a market cap of $175.55 million, a price-to-earnings ratio of 24.32 and a beta of 1.14. The company has a current ratio of 3.11, a quick ratio of 2.55 and a debt-to-equity ratio of 0.06. The firm has a fifty day simple moving average of $16.61 and a 200-day simple moving average of $18.05.
Analyst Upgrades and Downgrades
Separately, DA Davidson upgraded shares of Medifast from an “underperform” rating to a “neutral” rating and raised their target price for the stock from $16.50 to $17.00 in a research report on Tuesday, November 5th.
Medifast Company Profile
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Featured Stories
- Five stocks we like better than Medifast
- What is Forex and How Does it Work?
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- What Investors Need to Know to Beat the Market
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- What is a SEC Filing?
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.